You are here

Preliminary Analysis of Results From Neramexane Trial Fails To Achieve Statistical Significance

NEW YORK, Aug. 31 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. announced today that in a preliminary analysis, data from the first Phase III study of the investigational Alzheimer's disease treatment, neramexane, failed to achieve statistical significance. The six-month, double-blind, parallel-group Phase III study was designed to evaluate the safety and efficacy of combination therapy with neramexane and any of the three most widely prescribed acetylcholinesterase inhibitors (AChEI) compared to an AChEI alone in 415 outpatients with moderate to severe Alzheimer's disease. Early analysis of data indicates that patients receiving neramexane and an AChEI did not achieve a statistically significant difference compared to patients on an AChEI alone on the study's primary endpoints of cognition and function. The primary endpoints were the Severe Impairment Battery (SIB), a measure of cognition, and the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, modified for severe dementia (ADCS-ADLsev), a measure of functionality. The secondary endpoint, the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus), also failed to show statistical significance. There were no safety issues identified in the study. Further analysis of these data will be completed in the coming months.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Forest is currently enrolling moderate to severe Alzheimer's disease patients in a second Phase II/III study examining neramexane as monotherapy compared to placebo and plans to continue the clinical development of the compound.

About Neramexane

Neramexane is a cyclohexane derivative belonging to a class of drugs called N-methyl-D-aspartate (NMDA)-receptor antagonists. Neramexane is believed to selectively block the effects associated with abnormal transmission of glutamate (a neurotransmitter that performs an integral role in the neural pathways associated with learning and memory) while allowing for the physiological transmission associated with normal cell functioning. The abnormal transmission of glutamate and the related excitotoxic processes are believed to play a role in Alzheimer's disease.

Neramexane is being developed jointly by Forest and its licensor, Merz Pharmaceuticals, a German-based specialty pharmaceutical company dedicated to research and development in the fields of neurology and psychiatry.

Alzheimer's Disease

Alzheimer's is a progressive disease of the brain and it is the most common type of dementia. The term dementia is used to describe the progressive loss of cognitive, intellectual, or functional abilities. Published reports project that by 2050 more than 16 million people in the United States will have Alzheimer's disease.

Source: Forest Laboratories

Recent Headlines

Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over Half of Patients Had Reduced Pain Levels of 30% or More
Over 25% of Study Patients Showed 6–12 Months Remission
Researchers Extend Previous Data, Find Association is Reversed
First Anti-PD-1 Therapy Demonstrates Improved Overall Survival
New Test Could Prevent Short- and Long-term Complications